Extensive evidence supports the benefits of treating to glycated haemoglobin (HbA 1c ) goal, both in terms of health and economic outcomes. As shown by the UK Prospective Diabetes Study (UKPDS) and the Diabetes Control and Complications Trial (DCCT), the risk of patients with type 2 diabetes developing vascular complications is strongly correlated with HbA 1c levels and the duration of poor glycaemic control. Moreover, good glycaemic control significantly reduces the risk of complications. In controlled clinical trials, a number of pharmacological agents have been shown to significantly reduce HbA 1c levels in patients with type 2 diabetes. However, the reality is that most patients with type 2 diabetes have HbA 1c levels above the recommended target levels. Although there are regional differences in the average HbA 1c level, poor glycaemic control is a universal problem that will continue to grow in line with the rapidly increasing prevalence of type 2 diabetes. Barriers to good blood glucose control are present in almost every aspect of diabetes care. Furthermore, in patients with type 2 diabetes, therapy-, patient-and/or healthcare system-related barriers are compounded by an ongoing decline in beta-cell function that is characteristic of the progressive nature of the disease. Therapy-related barriers include reduced long-term efficacy with oral agents, fear of hypoglycaemia and a variety of issues related to flexibility and convenience that encourage poor compliance with therapy. From the patient perspective, issues relating to lifestyle, education, psychology and the environment can prevent optimum diabetes self-management. Poor access to and/or use of specialist healthcare resources also has a negative effect on treatment outcomes. These barriers to glycaemic control need to be overcome so that the established benefits of reducing glucose to normal or near-normal levels can be experienced by more people with type 2 diabetes.
Diabetes treatment goals
Before exploring some of the many challenges of treating to goal, it is necessary to answer the question 'What is the treatment goal?'. Diabetes is a complex disease that requires the management of glucose, blood pressure, lipid levels and thrombotic status. With respect to blood glucose goals -the focus of this article -glycated haemoglobin (HbA 1c ), fasting plasma glucose and postprandial plasma glucose levels can be measured to gauge the degree of metabolic control. Although it is desirable to normalise each of these glucose parameters, HbA 1c is generally used as the standard measurement for intervention and treatment.
Diabetes treatment goals can and indeed should be tailored for the individual patient, taking into consideration the stage of the disease, their commitment and ability to carry out self-care, the presence of comorbidities and the risk of hypoglycaemia. However, general diabetes treatment guidelines have been developed using data from several landmark diabetes intervention studies. The Diabetes Control and Complications Trial (DCCT) (1) and the Stockholm Diabetes Intervention Study (SDIS) (2) , both conducted in patients with type 1 diabetes, and the UK Prospective Diabetes Study (UKPDS) (3) and Kumamoto Study (4) , conducted in patients with type 2 diabetes, were particularly influential in this respect. As shown in Table 1 , the results of these studies have been interpreted differently by the various professional bodies and there is a lack of consensus across the treatment guidelines (5 -10). Target HbA 1c levels vary widely from approximately 6.2% to as high as 7.5% but, based on data from the UKPDS, the general consensus is an HbA 1c level of 7% or lower.
The importance of treating to goal
There is an extensive evidence base supporting the benefits of treating to HbA 1c goal. Above all, decreasing HbA 1c levels reduces the risk of vascular complications (11) -the principal cause of diabetes-related morbidity and mortality. Importantly, therapeutic interventions that reduce the risk of complications, i.e. interventions that reduce glycaemia and blood pressure, do not significantly reduce quality of life unlike the longterm complications of diabetes (11) . Diabetes-related healthcare costs increase substantially with the presence of long-term diabetes complications (12) . However, intensive glycaemic control can reduce healthcare costs by reducing the cost of treating complications (13, 14) .
The results of the DCCT showed a significant correlation between HbA 1c levels and the risk of microvascular complications (retinopathy, nephropathy, neuropathy and microalbinuria) in patients with type 1 diabetes (15) . The lower the HbA 1c level, the greater the reduction in the relative risk of developing any of the long-term complications. The risk of complications increased over time and was greatest in patients with a long history of poor glycaemic control (15) . A quarter of those patients who had HbA 1c . 11% (also defined as worst glycaemic control) had evidence of diabetic retinopathy after just 5 years. In contrast, those with good glycaemic control (HbA 1c , 7%) had a low risk of retinopathy for at least 10 years (15, 16) .
Similarly, the results of the UKPDS showed that poor glycaemic control increases the risk of long-term complications in people with type 2 diabetes. The risk of both micro-and macrovascular complications (after adjustment for age, sex, ethnic group and duration of diabetes) was strongly associated with hyperglycaemia, and the incidence increased three fold over the range of HbA 1c , 6% to HbA 1c $ 10% (17) . Extrapolation of data from the latter study showed that each 1% reduction in HbA 1c reduced the risk of microvascular complications by 37% (P , 0.0001) and the risk of fatal and non-fatal myocardial infarction by 14% (P , 0.0001) (Fig. 1 ). There was no threshold level of HbA 1c above or below which the risk of complications ceased to increase or decrease respectively (17) .
Most patients do not reach treatment goals
Despite evidence that good glycaemic control has significant health and economic benefits, most patients with diabetes do not achieve recommended treatment goals. According to studies conducted in the USA, Europe and Asia Pacific, most patients have poor glycaemic control (HbA 1c . 8%) and less than one-third, substantially less in some countries, achieve the recommended target levels for HbA 1c (18 -20) . For example, in the Diabcare-Asia Study (19), the mean HbA 1c level was 8.6%, with only 21, 13 or 7% of patients achieving recommended HbA 1c goals according to the criteria of the American Diabetes Association (ADA; , 7%), the European Diabetes Policy Group (EUDPG; # 6.5%) or the Asia Pacific Type 2 Diabetes Policy Group 1999 (APDPG; , 6.2%) ( Fig. 2; 19 , note that the APDPG 2002 guidelines recommend a goal # 6.5%). These data are supported by numerous other studies. For instance, in the UK Asian Diabetes Study, a community-based study conducted in Birmingham and Coventry in the UK, 66% of patients had HbA 1c . 7% (21) . Why are so many patients failing to receive the benefits of good glycaemic control?
Barriers to achieving glucose goals
Barriers to optimal glycaemic control are present in almost every aspect of diabetes care. Although significant advances have been made in the past few decades, there remain substantial limitations with current therapeutic options that may decrease patients' willingness to adhere to their medication. Furthermore, many patients and healthcare professionals underestimate the seriousness of diabetes and the importance of interventions to prevent long-term complications. There is a lack of training and education for health professionals, patients and their families. These problems are compounded by the progressive nature of the disease and the fact that most available treatment strategies fail to maintain glycaemic control in the long-term because of an ongoing decline in beta-cell function. There are many treatment options for patients with type 2 diabetes, and there are major discrepancies among healthcare professionals about the optimal treatment strategies and about the appropriate timing of the strategies to be employed. In patients with newly diagnosed type 2 diabetes, lifestyle intervention (diet and exercise) is widely accepted as first-line therapy. If lifestyle changes fail to bring about improvements in glycaemic control, there are a number of options. In general, the first step is to supplement lifestyle changes with oral agent monotherapy, followed by oral combination therapy should monotherapy fail. However, if treatment targets are still not achieved physicians must choose between adding a third oral agent, combination therapy with oral agents plus insulin, or insulin therapy alone. This multitude of treatment options means that patients may fail on several different regimens, and therefore experience long periods of poor glycaemic control, before receiving insulin. Although the merits of early combination treatment with oral agents and/or insulin have been emphasised, this message does not seem to have filtered down to the average healthcare provider and, consequently, insulin therapy is inappropriately delayed in many patients who could otherwise benefit earlier from improved glycaemic control.
Therapeutic barriers
In addition to the reduced long-term efficacy with oral agents, current diabetes therapies lack flexibility for both patients and prescribers. For example, patients taking standard insulin formulations must adjust the timing and content of their meals to suit their insulin injection regimen.
Multiple daily insulin injections and/or a high pill load contribute to the daily burden of living with diabetes and can discourage adherence to therapy. Polypharmacy is a major reason for non-compliance with therapy (22); patients with type 2 diabetes may need to take as many as 16 tablets a day plus insulin injections to control glycaemia, blood pressure and cardiovascular (CVD) risk factors. Morris et al. (23) , demonstrated that adequate adherence with treatment (defined as having prescriptions filled often enough to enable the person to take at least 90% of the recommended dosage of each medication) more than halved when patients were switched from monotherapy with a sulphonylurea or metformin to combination therapy with a sulphonylurea plus metformin.
Using current therapeutic options, there is a trade-off between the benefits of intensive glycaemic control and increased risk of hypoglycaemia -perhaps the greatest fear of insulin-treated type 1 and type 2 diabetes patients. In the DCCT for example, the lower risk of complications associated with intensive insulin therapy compared with conventional therapy was at the expense of increased risk of severe hypoglycaemia (1). Patients receiving intensive therapy were 2-3 times more likely to experience a severe hypoglycaemic episode than those receiving conventional therapy (1). In the UKPDS, patients receiving intensive therapy with a sulphonylurea or insulin were also significantly more likely to experience a hypoglycaemic event than those receiving conventional therapy (P , 0.0001) (2) . Thus, fear of hypoglycaemia is likely to be an important barrier to achieving blood glucose targets. Numerous other therapy-related barriers such as cost, availability of diagnostic tools, supply issues and fear of injections may prevent patients from achieving good glycaemic control (see 24 for review).
Patient-related barriers
A variety of issues relating to lifestyle, education, psychology and the environment can impair diabetes self-management. Behavioural and medical barriers, such as obesity, physical inactivity, substance abuse, smoking and non-compliance with therapy, are often closely interrelated. It is therefore important for physicians to understand the barriers to glycaemic control from the patient's perspective and to combine psychosocial support with appropriate pharmacological therapy (25) . Emotional well-being is critical for effective self-care (26) and depression, which is common among people with diabetes, is likely to have a major effect on patients' attitudes to therapy and, ultimately, treatment outcomes. Patient-related barriers to achieving glucose goals are discussed in further detail in the following articles (27 -30) .
Healthcare system-related barriers
Poor access and/or use of specialist care can also affect treatment outcomes. In a study in patients with type 1 diabetes, the longer the proportion of diabetes duration spent in specialist care, the lower the risk of overt nephropathy (risk ratio 0.43, 95% CI 0.21 -0.88), neuropathy (risk ratio 0.54, 95% CI 0.35 -0.83) and coronary artery disease (risk ratio 0.65, 95% CI 0.37 -1.1). This trend was independent of diabetes duration, demographic characteristics, healthcare practices and physiological risk factors (31) . Thus, specialist rather than general diabetes care may result in better glycaemic control and a lower incidence of some diabetes complications.
Regional and cultural differences in glycaemic control
Intercultural differences exist in the proportion of patients achieving good glycaemic control (32 (33) . However, irrespective of race or ethnicity, the data consistently show that the majority of patients with diabetes do not reach the recommended treatment goals, as shown across 12 countries in the Diabcare-Asia study (19) .
Conclusions
The rising incidence of type 2 diabetes and associated burden of diabetes-related complications mean that the management of diabetes must be improved. There are multiple barriers to optimal glycaemic control that need to be overcome so that the established benefits of good glycaemic control can be experienced by more people with diabetes. The following papers in this supplement (27) (28) (29) (30) show that breaking down these barriers requires that treatment goals and strategies are individualised, bearing in mind patients' needs and goals as well as socioeconomic, psychological and pathophysiological factors. In addition, new treatment options that offer superior flexibility, convenience and acceptability will help to implement more effective diabetes management strategies and to improve diabetes outcomes.
